Benitec Biopharma Inc.
Price Action
Technical Summary
CONSOLIDATINGBenitec Biopharma Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 48), showing significant lag compared to the market leaders. Investors should exercise caution due to high volatility (60% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $11.53 | +10.15% | ABOVE |
| 50 SMA | $11.85 | +7.18% | ABOVE |
| 100 SMA | $11.60 | +9.49% | ABOVE |
| 150 SMA | $11.90 | +6.74% | ABOVE |
| 200 SMA | $12.53 | +1.35% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is BNTC in an uptrend right now?
BNTC has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is BNTC overbought or oversold?
BNTC's RSI (14) is 56. The stock is in neutral territory, neither overbought nor oversold.
Is BNTC outperforming the market?
BNTC has a Relative Strength (RS) Rating of 48 out of 99. BNTC is currently lagging the broader market.
Where is BNTC in its 52-week range?
BNTC is trading at $12.70, which is 76% of its 52-week high ($16.76) and 41% above its 52-week low ($9.93).
How volatile is BNTC?
BNTC has a Beta of 1.51 and 52-week volatility of 60%. It's more volatile than the S&P 500 - expect bigger swings.